{"id":759,"date":"2019-02-05T11:53:43","date_gmt":"2019-02-05T08:53:43","guid":{"rendered":"http:\/\/kliniki.webproposal.eu\/?page_id=759"},"modified":"2019-02-18T12:38:28","modified_gmt":"2019-02-18T09:38:28","slug":"aimatologiko-dimosieuseis","status":"publish","type":"page","link":"https:\/\/www.appk.gr\/en\/aimatologiko-dimosieuseis\/","title":{"rendered":"Haematology \u2013 Publications"},"content":{"rendered":"

HAEMATOLOGY DEPARTMENT \u2013 PUBLICATION (2015-2018) <\/strong><\/p>\r\n

 The outcome of patients with high-risk MDS achieving stable disease after treatment with 5-azacytidine: A retrospective analysis of the Hellenic (Greek) MDS Study Group.<\/a><\/p>\r\n

Papageorgiou SG, Kontos CK, Kotsianidis I, Vasilatou D, Symeonidis A, Galanopoulos A, Bouchla A, Hatzimichael E, Repousis P, Zikos P, Viniou NA, Poulakidas E, Vassilakopoulos TP, Diamantopoulos P, Diamantopoulos MA, Mparmparousi D, Bouronikou E, Papadaki H, Panayiotidis P, Pappa V.<\/p>\r\n

Hematol Oncol. 2018 Oct;36(4):693-700. doi: 10.1002\/hon.2551. Epub 2018 Sep 7.<\/p>\r\n

PMID: 30129144<\/p>\r\n

 <\/p>\r\n

Positive impact of brentuximab vedotin on overall survival of patients with classical Hodgkin lymphoma who relapse or progress after autologous stem cell transplantation: A nationwide analysis.<\/a><\/p>\r\n

Tsirigotis P, Vassilakopoulos T, Batsis I, Bousiou Z, Gkirkas K, Sakellari I, Kaloyannidis P, Roussou P, Pangalis GA, Moschogiannis M, Vassilopoulos G, Repousis P, Megalakaki A, Michalis E, Kalpadakis C, Papadaki HA, Kotsianidis I, Hatzimichael E, Spyridonidis A, Anargyrou K, Poulakidas E, Giannoullia P, Apostolidis I, Stamouli M, Konstantopoulos K, Pappa V, Panayiotidis P, Harhalakis N, Anagnostopoulos A, Angelopoulou M.<\/p>\r\n

Hematol Oncol. 2018 Oct;36(4):645-650. doi: 10.1002\/hon.2521. Epub 2018 Jun 8.<\/p>\r\n

PMID: 29882363<\/p>\r\n

 <\/p>\r\n

Correction to: Real-world data on Len\/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival.<\/a><\/p>\r\n

Katodritou E, Kyrtsonis MC, Delimpasi S, Kyriakou D, Symeonidis A, Spanoudakis E, Vasilopoulos G, Anagnostopoulos A, Kioumi A, Zikos P, Aktypi A, Briasoulis E, Megalakaki A, Repousis P, Adamopoulos I, Gogos D, Kotsopoulou M, Pappa V, Papadaki E, Fotiou D, Nikolaou E, Giannopoulou E, Hatzimichael E, Giannakoulas N, Douka V, Kokoviadou K, Timotheatou D, Terpos E.<\/p>\r\n

Ann Hematol. 2018 Sep;97(9):1747. doi: 10.1007\/s00277-018-3404-8.<\/p>\r\n

PMID: 29943159<\/p>\r\n

 <\/p>\r\n

Real-world data on Len\/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival.<\/a><\/p>\r\n

Katodritou E, Kyrtsonis MC, Delimpasi S, Kyriakou D, Symeonidis A, Spanoudakis E, Vasilopoulos G, Anagnostopoulos A, Kioumi A, Zikos P, Aktypi A, Briasoulis E, Megalakaki A, Repousis P, Adamopoulos I, Gogos D, Kotsopoulou M, Pappa V, Papadaki E, Fotiou D, Nikolaou E, Giannopoulou E, Hatzimichael E, Giannakoulas N, Douka V, Kokoviadou K, Timotheatou D, Terpos E.<\/p>\r\n

Ann Hematol. 2018 Sep;97(9):1671-1682. doi: 10.1007\/s00277-018-3361-2. Epub 2018 May 13. Erratum in: Ann Hematol. 2018 Jun 26;:<\/a>.<\/p>\r\n

PMID: 29756171<\/p>\r\n

 <\/p>\r\n

Body mass index and relative dose intensity does not affect the response and outcome of high-risk MDS patients treated with azacytidine. Results from the Hellenic (Greek) MDS study group.<\/a><\/p>\r\n

Papageorgiou SG, Kotsianidis I, Kontos CK, Symeonidis A, Galanopoulos A, Hatzimichael E, Poulakidas E, Diamantopoulos P, Vassilakopoulos TP, Zikos P, Papadaki H, Bouronikou E, Panayiotidis P, Viniou NA, Pappa V.<\/p>\r\n

Leuk Res. 2018 Aug;71:55-59. doi: 10.1016\/j.leukres.2018.07.004. Epub 2018 Jul 7. No abstract available.<\/p>\r\n

PMID: 30007218<\/p>\r\n

 <\/p>\r\n

Efficacy-safety of Facilitated Subcutaneous Immunoglobulin in Immunodeficiency Due to Hematological Malignancies. A Single-Center Retrospective Analysis.<\/a><\/p>\r\n

Dimou M, Iliakis T, Maltezas D, Bitsani A, Kalyva S, Koudouna A, Kotsanti S, Petsa P, Papaioannou P, Kyrtsonis MC, Panayiotidis P.<\/p>\r\n

Anticancer Res. 2018 Jul;38(7):4187-4191. doi: 10.21873\/anticanres.12712.<\/p>\r\n

PMID: 29970548<\/p>\r\n

 <\/p>\r\n

Phase 3 Trial of Ibrutinib plus Rituximab in Waldenstr\u00f6m’s Macroglobulinemia.<\/a><\/p>\r\n

Dimopoulos MA, Tedeschi A, Trotman J, Garc\u00eda-Sanz R, Macdonald D, Leblond V, Mahe B, Herbaux C, Tam C, Orsucci L, Palomba ML, Matous JV, Shustik C, Kastritis E, Treon SP, Li J, Salman Z, Graef T, Buske C; iNNOVATE Study Group and the European Consortium for Waldenstr\u00f6m\u2019s Macroglobulinemia.<\/p>\r\n

N Engl J Med. 2018 Jun 21;378(25):2399-2410. doi: 10.1056\/NEJMoa1802917. Epub 2018 Jun 1.<\/p>\r\n

PMID: 29856685<\/p>\r\n

 <\/p>\r\n

Primary Hepatic Burkitt Lymphoma in a Kidney Transplant Recipient.<\/a><\/p>\r\n

Lionaki S, Tsakonas E, Androulaki A, Liapis G, Panayiotidis P, Zavos G, Boletis JN.<\/p>\r\n

Case Rep Nephrol. 2018 May 13;2018:7425785. doi: 10.1155\/2018\/7425785. eCollection 2018.<\/p>\r\n

PMID: 29862100<\/p>\r\n

 <\/p>\r\n

Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial.<\/a><\/p>\r\n

Saussele S, Richter J, Guilhot J, Gruber FX, Hjorth-Hansen H, Almeida A, Janssen JJWM, Mayer J, Koskenvesa P, Panayiotidis P, Olsson-Str\u00f6mberg U, Martinez-Lopez J, Rousselot P, Vestergaard H, Ehrencrona H, Kairisto V, Machov\u00e1 Pol\u00e1kov\u00e1 K, M\u00fcller MC, Mustjoki S, Berger MG, Fabarius A, Hofmann WK, Hochhaus A, Pfirrmann M, Mahon FX; EURO-SKI investigators.<\/p>\r\n

Lancet Oncol. 2018 Jun;19(6):747-757. doi: 10.1016\/S1470-2045(18)30192-X. Epub 2018 May 4.<\/p>\r\n

PMID: 29735299<\/p>\r\n

 <\/p>\r\n

The prognostic value of monosomal karyotype (MK) in higher-risk patients with myelodysplastic syndromes treated with 5-Azacitidine: A retrospective analysis of the Hellenic (Greek) Myelodysplastic syndromes Study Group.<\/a><\/p>\r\n

Papageorgiou SG, Vasilatou D, Kontos CK, Kotsianidis I, Symeonidis A, Galanopoulos AG, Hatzimichael E, Megalakaki A, Poulakidas E, Diamantopoulos P, Vassilakopoulos TP, Zikos P, Papadaki H, Mparmparousi D, Bouronikou E, Panayiotidis P, Viniou NA, Pappa V.<\/p>\r\n

Am J Hematol. 2018 Jul;93(7):895-901. doi: 10.1002\/ajh.25111. Epub 2018 May 16.<\/p>\r\n

PMID: 29659040<\/p>\r\n

 <\/p>\r\n

Study of bone metabolism and angiogenesis in patients undergoing high-dose chemotherapy\/autologous hematopoietic stem cell transplantation.<\/a><\/p>\r\n

Boutsikas G, Terpos E, Papatheodorou A, Tsirkinidis P, Tsirigotis P, Meletiou A, Lalou E, Telonis V, Zannou A, Kanellopoulos A, Galani Z, Stefanou A, Tsaftaridis P, Viniou NA, Panayiotidis P, Kyrtsonis MC, Meletis J, Vassilakopoulos TP, Angelopoulou MK.<\/p>\r\n

Eur J Haematol. 2018 Feb;100(2):131-139. doi: 10.1111\/ejh.12990. Epub 2017 Dec 4.<\/p>\r\n

PMID: 29105864<\/p>\r\n

 <\/p>\r\n

Brentuximab vedotin in relapsed\/refractory Hodgkin lymphoma. The Hellenic experience.<\/a><\/p>\r\n

Angelopoulou MK, Vassilakopoulos TP, Batsis I, Sakellari I, Gkirkas K, Pappa V, Giannoulia P, Apostolidis I, Apostolopoulos C, Roussou P, Panayiotidis P, Dimou M, Kyrtsonis MC, Palassopoulou M, Vassilopoulos G, Moschogiannis M, Kalpadakis C, Margaritis D, Spyridonidis A, Michalis E, Anargyrou K, Repousis P, Hatzimichael E, Bousiou Z, Poulakidas E, Grentzelias D, Harhalakis N, Pangalis GA, Anagnostopoulos A, Tsirigotis P.<\/p>\r\n

Hematol Oncol. 2018 Feb;36(1):174-181. doi: 10.1002\/hon.2383. Epub 2017 Feb 20.<\/p>\r\n

PMID: 28219112<\/p>\r\n

 <\/p>\r\n

Evaluation of the performance of tuberculin skin test and Quantiferon-TB gold in tube test in patients with hematologic malignancies.<\/a><\/p>\r\n

Diamantopoulos PT, Tsilimidos GD, Zervakis K, Polonyfi K, Sofotasiou M, Kyrtsonis MC, Aessopos A, Kyriakakis G, Viniou NA.<\/p>\r\n

Infect Dis (Lond). 2017 Jul;49(7):545-548. doi: 10.1080\/23744235.2017.1280619. Epub 2017 Jan 25. No abstract available. Erratum in: Infect Dis (Lond). 2017 Nov – Dec;49(11-12):878<\/a>.<\/p>\r\n

PMID: 28121214<\/p>\r\n

 <\/p>\r\n

Hypercalcemia remains an adverse prognostic factor for newly diagnosed multiple myeloma patients in the era of novel antimyeloma therapies.<\/a><\/p>\r\n

Zagouri F, Kastritis E, Zomas A, Terpos E, Katodritou E, Symeonidis A, Delimpasi S, Pouli A, Vassilakopoulos TP, Michalis E, Giannouli S, Kartasis Z, Christoforidou A, Kokoviadou K, Hatzimichael E, Gika D, Megalakaki C, Papaioannou M, Kyrtsonis MC, Konstantopoulos K, Dimopoulos MA; Greek Myeloma Study Group.<\/p>\r\n

Eur J Haematol. 2017 Nov;99(5):409-414. doi: 10.1111\/ejh.12923. Epub 2017 Sep 26.<\/p>\r\n

PMID: 28675766<\/p>\r\n

 <\/p>\r\n

The Significance of PET\/CT in the Initial Staging of Hodgkin Lymphoma: Experience Outside Clinical Trials.<\/a><\/p>\r\n

Angelopoulou MK, Mosa E, Pangalis GA, Rondogianni P, Chatziioannou S, Prassopoulos V, Moschogianni M, Tsirkinidis P, Asimakopoulos JV, Konstantinou I, Tsourouflis G, Sachanas S, Yiakoumis X, Boutsikas G, Arapaki M, Gainaru G, Kyrtsonis MC, Siakantaris MP, Datseris I, Panayiotidis P, Konstantopoulos K, Vassilakopoulos TP.<\/p>\r\n

Anticancer Res. 2017 Oct;37(10):5727-5736.<\/p>\r\n

PMID: 28982893<\/p>\r\n

 <\/p>\r\n

Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma.<\/a><\/p>\r\n

Dreyling M, Santoro A, Mollica L, Lepp\u00e4 S, Follows GA, Lenz G, Kim WS, Nagler A, Panayiotidis P, Demeter J, \u00d6zcan M, Kosinova M, Bouabdallah K, Morschhauser F, Stevens DA, Trevarthen D, Giurescu M, Cupit L, Liu L, K\u00f6chert K, Seidel H, Pe\u00f1a C, Yin S, Hiemeyer F, Garcia-Vargas J, Childs BH, Zinzani PL.<\/p>\r\n

J Clin Oncol. 2017 Dec 10;35(35):3898-3905. doi: 10.1200\/JCO.2017.75.4648. Epub 2017 Oct 4.<\/p>\r\n

PMID: 28976790<\/p>\r\n

 <\/p>\r\n

High-grade B-cell lymphoma of the peritoneum as a result of transformation of a CD5-negative monoclonal B lymphocytosis population in a patient with myelodysplastic syndrome treated with 5-azacytidine.<\/a><\/p>\r\n

Dimou M, Roumelioti M, Dimitrakopoulou A, Bitsani C, Kotsanti S, Petsa P, Papaioannou P, Kyrtsonis MC, Panayiotidis P.<\/p>\r\n

Leuk Lymphoma. 2018 May;59(5):1264-1267. doi: 10.1080\/10428194.2017.1375108. Epub 2017 Sep 13. No abstract available.<\/p>\r\n

PMID: 28901815<\/p>\r\n

 <\/p>\r\n

Bone metabolism markers and angiogenic cytokines as regulators of human hematopoietic stem cell mobilization.<\/a><\/p>\r\n

Tsirkinidis P, Terpos E, Boutsikas G, Papatheodorou A, Anargyrou K, Lalou E, Dimitrakopoulou A, Kalpadakis C, Konstantopoulos K, Siakantaris M, Panayiotidis P, Pangalis G, Kyrtsonis MC, Vassilakopoulos T, Angelopoulou MK.<\/p>\r\n

J Bone Miner Metab. 2018 Jul;36(4):399-409. doi: 10.1007\/s00774-017-0853-4. Epub 2017 Jun 28.<\/p>\r\n

PMID: 28660376<\/p>\r\n

 <\/p>\r\n

Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group.<\/a><\/p>\r\n

Katodritou E, Terpos E, Delimpasi S, Kotsopoulou M, Michalis E, Vadikolia C, Kyrtsonis MC, Symeonidis A, Giannakoulas N, Vadikolia C, Michael M, Kalpadakis C, Gougopoulou T, Prokopiou C, Kaiafa G, Christoulas D, Gavriatopoulou M, Giannopoulou E, Labropoulou V, Verrou E, Kastritis E, Konstantinidou P, Anagnostopoulos A, Dimopoulos MA.<\/p>\r\n

Blood Cancer J. 2018 Mar 9;8(3):31. doi: 10.1038\/s41408-018-0059-6.<\/p>\r\n

PMID: 29523783<\/p>\r\n

 <\/p>\r\n

Brentuximab vedotin in relapsed\/refractory Hodgkin lymphoma. The Hellenic experience.<\/a><\/p>\r\n

Angelopoulou MK, Vassilakopoulos TP, Batsis I, Sakellari I, Gkirkas K, Pappa V, Giannoulia P, Apostolidis I, Apostolopoulos C, Roussou P, Panayiotidis P, Dimou M, Kyrtsonis MC, Palassopoulou M, Vassilopoulos G, Moschogiannis M, Kalpadakis C, Margaritis D, Spyridonidis A, Michalis E, Anargyrou K, Repousis P, Hatzimichael E, Bousiou Z, Poulakidas E, Grentzelias D, Harhalakis N, Pangalis GA, Anagnostopoulos A, Tsirigotis P.<\/p>\r\n

Hematol Oncol. 2018 Feb;36(1):174-181. doi: 10.1002\/hon.2383. Epub 2017 Feb 20.<\/p>\r\n

PMID: 28219112<\/p>\r\n

 <\/p>\r\n

Detection of L265P MYD-88 mutation in a series of clonal B-cell lymphocytosis of marginal zone origin (CBL-MZ).<\/a><\/p>\r\n

Kalpadakis C, Pangalis GA, Vassilakopoulos TP, Roumelioti M, Sachanas S, Korkolopoulou P, Koulieris E, Moschogiannis M, Yiakoumis X, Tsirkinidis P, Pontikoglou C, Rondoyianni D, Papadaki HA, Panayiotidis P, Angelopoulou MK.<\/p>\r\n

Hematol Oncol. 2017 Dec;35(4):542-547. doi: 10.1002\/hon.2361. Epub 2016 Oct 13.<\/p>\r\n

PMID: 27734522<\/p>\r\n

 <\/p>\r\n

Thioredoxin-1, chemokine (C-X-C motif) ligand-9 and interferon-\u03b3 expression in the neoplastic cells and macrophages of Hodgkin lymphoma: clinicopathologic correlations and potential prognostic implications.<\/a><\/p>\r\n

P Vassilakopoulos T, Levidou G, Milionis V, Hartmann S, Lakiotaki E, Sepsa A, Thymara I, Ntailiani P, Spanou K, K Angelopoulou M, P Siakantaris M, Moschogiannis M, A Pangalis G, Panayiotidis P, Konstantopoulos K, Patsouris E, Hansmann ML, Korkolopoulou P.<\/p>\r\n

Leuk Lymphoma. 2017 Sep;58(9):1-13. doi: 10.1080\/10428194.2017.1289520. Epub 2017 Jun 2.<\/p>\r\n

PMID: 28571489<\/p>\r\n

 <\/p>\r\n

Cadherin-11 (CDH11) expression in the peripheral blood of patients with active Multiple Myeloma.<\/a><\/p>\r\n

Christopoulos PF, Sfikakis PP, Nikolaou E, Terpos E, Koutsilieris M, Kyrtsonis MC.<\/p>\r\n

Br J Haematol. 2017 Jun;177(5):813-816. doi: 10.1111\/bjh.14105. Epub 2016 Apr 26. No abstract available.<\/p>\r\n

PMID: 27118219<\/p>\r\n

 <\/p>\r\n

Ibrutinib for patients with rituximab-refractory Waldenstr\u00f6m’s macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial.<\/a><\/p>\r\n

Dimopoulos MA, Trotman J, Tedeschi A, Matous JV, Macdonald D, Tam C, Tournilhac O, Ma S, Oriol A, Heffner LT, Shustik C, Garc\u00eda-Sanz R, Cornell RF, de Larrea CF, Castillo JJ, Granell M, Kyrtsonis MC, Leblond V, Symeonidis A, Kastritis E, Singh P, Li J, Graef T, Bilotti E, Treon S, Buske C; iNNOVATE Study Group and the European Consortium for Waldenstr\u00f6m’s Macroglobulinemia.<\/p>\r\n

Lancet Oncol. 2017 Feb;18(2):241-250. doi: 10.1016\/S1470-2045(16)30632-5. Epub 2016 Dec 10.<\/p>\r\n

PMID: 27956157<\/p>\r\n

 <\/p>\r\n

BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow-up of 6 years.<\/a><\/p>\r\n

Gavriatopoulou M, Garc\u00eda-Sanz R, Kastritis E, Morel P, Kyrtsonis MC, Michalis E, Kartasis Z, Leleu X, Palladini G, Tedeschi A, Gika D, Merlini G, Sonneveld P, Dimopoulos MA.<\/p>\r\n

Blood. 2017 Jan 26;129(4):456-459. doi: 10.1182\/blood-2016-09-742411. Epub 2016 Nov 21.<\/p>\r\n

PMID: 27872060<\/p>\r\n

 <\/p>\r\n

New evidence of gene inactivation by aberrant DNA-Methylation in T-cell leukemia, with treatment implications.<\/a><\/p>\r\n

Kyrtsonis MC, Maltezas D.<\/p>\r\n

Leuk Res. 2016 Nov;50:29-30. doi: 10.1016\/j.leukres.2016.09.010. Epub 2016 Sep 6. No abstract available.<\/p>\r\n

PMID: 27649494<\/p>\r\n

 <\/p>\r\n

Extramedullary sudden blast crisis in chronic-phase chronic myeloid leukemia during first-line treatment with nilotinib.<\/a><\/p>\r\n

Angelopoulou MK, Asimakopoulos JV, Galani Z, Levidou G, Roumelioti M, Vassilakopoulos TP, Korkolopoulou P, Panayiotidis P.<\/p>\r\n

Blood Cancer J. 2016 Aug 26;6(8):e461. doi: 10.1038\/bcj.2016.66. No abstract available.<\/p>\r\n

PMID: 27564459<\/p>\r\n

 <\/p>\r\n

Response to ‘PET after response to R-CHOP in primary mediastinal large B-cell lymphoma’.<\/a><\/p>\r\n

Vassilakopoulos TP, Papageorgiou S, Pangalis GA, Chatziioannou S, Angelopoulou MK,Panayiotidis P, Konstantopoulos K, Rondogianni P.<\/p>\r\n

Leukemia. 2016 Aug;30(8):1800-1. doi: 10.1038\/leu.2016.109. Epub 2016 Jun 3. No abstract available.<\/p>\r\n

PMID: 27256701<\/p>\r\n

 <\/p>\r\n

A phase 2, multicenter study investigating ofatumumab and bendamustine combination in patients with untreated or relapsed CLL.<\/a><\/p>\r\n

Flinn IW, Panayiotidis P, Afanasyev B, Janssens A, Grosicki S, Homenda W, Smolej L, Kuliczkowski K, Doubek M, Domnikova N, West SL, Chang CN, Barker AM, Gupta IV, Wright OJ, Offner F.<\/p>\r\n

Am J Hematol. 2016 Sep;91(9):900-6. doi: 10.1002\/ajh.24430. Epub 2016 Jul 3.<\/p>\r\n

PMID: 27222473<\/p>\r\n

 <\/p>\r\n

Phase 2 study of ofatumumab, fludarabine and cyclophosphamide in relapsed\/refractory Waldenstr\u00f6m’s macroglobulinemia.<\/a><\/p>\r\n

Gavriatopoulou M, Kastritis E, Kyrtsonis MC, Vassilakopoulos TP, Roussou M, Fotiou D, Migkou M, Mpakiri M, Tasidou A, Terpos E, Dimopoulos MA.<\/p>\r\n

Leuk Lymphoma. 2017 Jun;58(6):1506-1508. doi: 10.1080\/10428194.2016.1233541. Epub 2016 Oct 10. No abstract available.<\/p>\r\n

PMID: 27724158<\/p>\r\n

 <\/p>\r\n

Prognostic significance of signal transducer and activator of transcription 5 and 5b expression in Epstein-Barr virus-positive patients with chronic lymphocytic leukemia.<\/a><\/p>\r\n

Diamantopoulos PT, Sofotasiou M, Georgoussi Z, Giannakopoulou N, Papadopoulou V, Galanopoulos A, Kontandreopoulou E, Zervakis P, Pallaki P, Kalala F, Kyrtsonis MC, Dimitrakopoulou A, Vassilakopoulos T, Angelopoulou M, Spanakis N, Viniou NA.<\/p>\r\n

Cancer Med. 2016 Sep;5(9):2240-8. doi: 10.1002\/cam4.804. Epub 2016 Jul 1.<\/p>\r\n

PMID: 27367207<\/p>\r\n

 <\/p>\r\n

Prognostic Implication of the Absolute Lymphocyte to Absolute Monocyte Count Ratio in Patients With Classical Hodgkin Lymphoma Treated With Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine or Equivalent Regimens.<\/a><\/p>\r\n

Vassilakopoulos TP, Dimopoulou MN, Angelopoulou MK, Petevi K, Pangalis GA, Moschogiannis M, Dimou M, Boutsikas G, Kanellopoulos A, Gainaru G, Plata E, Flevari P, Koutsi K, Papageorgiou L, Telonis V, Tsaftaridis P, Sachanas S, Yiakoumis X, Tsirkinidis P, Viniou NA, Siakantaris MP, Variami E, Kyrtsonis MC, Meletis J, Panayiotidis P, Konstantopoulos K.<\/p>\r\n

Oncologist. 2016 Mar;21(3):343-53. doi: 10.1634\/theoncologist.2015-0251. Epub 2016 Feb 26.<\/p>\r\n

PMID:26921291<\/p>\r\n

 <\/p>\r\n

Potential role of AKT\/mTOR signalling proteins in hairy cell leukaemia: association with BRAF\/ERK activation and clinical outcome.<\/a><\/p>\r\n

Lakiotaki E, Levidou G, Angelopoulou MK, Adamopoulos C, Pangalis G, Rassidakis G, Vassilakopoulos T, Gainaru G, Flevari P, Sachanas S, Saetta AA, Sepsa A, Moschogiannis M, Kalpadakis C, Tsesmetzis N, Milionis V, Chatziandreou I, Thymara I, Panayiotidis P, Dimopoulou M, Plata E, Konstantopoulos K, Patsouris E, Piperi C, Korkolopoulou P.<\/p>\r\n

Sci Rep. 2016 Feb 19;6:21252. doi: 10.1038\/srep21252.<\/p>\r\n

PMID: 26893254<\/p>\r\n

 <\/p>\r\n

Expression, prognostic significance and mutational analysis of protein tyrosine phosphatase SHP-1 in chronic myeloid leukemia.<\/a><\/p>\r\n

Papadopoulou V, Kontandreopoulou E, Panayiotidis P, Roumelioti M, Angelopoulou M, Kyriazopoulou L, Diamantopoulos PT, Vaiopoulos G, Variami E, Kotsianidis I, Athina Viniou N.<\/p>\r\n

Leuk Lymphoma. 2016 May;57(5):1182-8. doi: 10.3109\/10428194.2015.1090573. Epub 2015 Dec 23.<\/p>\r\n

PMID: 26373709<\/p>\r\n

 <\/p>\r\n

The role of magnetic resonance imaging in the evaluation of transfusional iron overload in myelodysplastic syndromes.<\/a><\/p>\r\n

Petrou E, Mavrogeni S, Karali V, Kolovou G, Kyrtsonis MC, Sfikakis PP, Panayiotidis P.<\/p>\r\n

Rev Bras Hematol Hemoter. 2015 Jul-Aug;37(4):252-8. doi: 10.1016\/j.bjhh.2015.03.014. Epub 2015 May 19.<\/p>\r\n

PMID: 26190429<\/p>\r\n

 <\/p>\r\n

PET\/CT in primary mediastinal large B-cell lymphoma responding to rituximab-CHOP: An analysis of 106 patients regarding prognostic significance and implications for subsequent radiotherapy.<\/a><\/p>\r\n

Vassilakopoulos TP, Pangalis GA, Chatziioannou S, Papageorgiou S, Angelopoulou MK, Galani Z, Kourti G, Prassopoulos V, Leonidopoulou T, Terpos E, Dimopoulou MN, Sachanas S, Kalpadakis C, Konstantinidou P, Boutsis D, Stefanoudaki E, Kyriazopoulou L, Siakantaris MP, Kyrtsonis MC, Variami E, Kotsianidis I, Symeonidis A, Michali E, Katodritou E, Kokkini G, Tsatalas C, Papadaki H, Dimopoulos MA, Sotiropoulos V, Pappa V, Karmiris T, Meletis J, Apostolidis J, Datseris I,Panayiotidis P, Konstantopoulos K, Roussou P, Rondogianni P.<\/p>\r\n

Leukemia. 2016 Jan;30(1):238-42. doi: 10.1038\/leu.2015.120. Epub 2015 May 14. No abstract available.<\/p>\r\n

PMID: 25971363<\/p>\r\n

 <\/p>\r\n

Lack of survival improvement with novel anti-myeloma agents for patients with multiple myeloma and central nervous system involvement: the Greek Myeloma Study Group experience.<\/a><\/p>\r\n

Katodritou E, Terpos E, Kastritis E, Delimpasis S, Symeonidis AS, Repousis P, Kyrtsonis MC, Vadikolia C, Michalis E, Polychronidou G, Michael M, Papadaki S, Papathanasiou M, Kokoviadou K, Kioumi A, Vlachaki E, Hadjiaggelidou C, Kouraklis A, Patsias I, Gavriatopoulou M, Kotsopoulou M, Verrou E, Gastari V, Christoulas D, Giannopoulou E, Pouli A, Konstantinidou P, Anagnostopoulos A, Dimopoulos MA.<\/p>\r\n

Ann Hematol. 2015 Dec;94(12):2033-42. doi: 10.1007\/s00277-015-2484-y. Epub 2015 Sep 30.<\/p>\r\n

PMID:26420061<\/p>\r\n

 <\/p>\r\n

Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenstr\u00f6m macroglobulinemia: final analysis of a phase 2 study.<\/a><\/p>\r\n

Kastritis E, Gavriatopoulou M, Kyrtsonis MC, Roussou M, Hadjiharissi E, Symeonidis A, Repoussis P, Michalis E, Delimpasi S, Tsatalas K, Tsirigotis P, Vassou A, Vervessou E, Katodritou E, Gika D, Terpos E, Dimopoulos MA.<\/p>\r\n

Blood. 2015 Sep 10;126(11):1392-4. doi: 10.1182\/blood-2015-05-647420. No abstract available.<\/p>\r\n

PMID: 26359434<\/p>\r\n

 <\/p>\r\n

Competing risk survival analysis in patients with symptomatic Waldenstr\u00f6m macroglobulinemia: the impact of disease unrelated mortality and of rituximab-based primary therapy.<\/a><\/p>\r\n

Kastritis E, Kyrtsonis MC, Morel P, Gavriatopoulou M, Hatjiharissi E, Symeonidis AS, Vassou A, Repousis P, Delimpasi S, Sioni A, Michalis E, Michael M, Vervessou E, Voulgarelis M, Tsatalas C, Terpos E, Dimopoulos MA.<\/p>\r\n

Haematologica. 2015 Nov;100(11):e446-9. doi: 10.3324\/haematol.2015.124149. Epub 2015 Aug 20. No abstract available.<\/p>\r\n

PMID: 26294729<\/p>\r\n

 <\/p>\r\n

Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT) with concurrent high grade component at diagnosis: clinico-pathologic features and treatment strategy.<\/a><\/p>\r\n

Sachanas S, Pangalis GA, Kalpadakis C, Levidou G, Yiakoumis X, Moschogiannis M, Kyrtsonis MC, Vassilakopoulos TP, Tsirkinidis P, Siakantaris M, Spiliadi C, Karagianni E, Korkolopoulou P, Rontogianni D, Papadaki H, Panayiotidis P, Angelopoulou M.<\/p>\r\n

Leuk Lymphoma. 2015;56(11):3230-2. doi: 10.3109\/10428194.2015.1034698. Epub 2015 May 12. No abstract available.<\/p>\r\n

PMID: 25827212<\/p>\r\n

 <\/p>\r\n

New insights into malignant B-cell disorders.<\/a><\/p>\r\n

Kyrtsonis MC, Shimizu K, Panayiotidis P, Pangalis GA.<\/p>\r\n

Biomed Res Int. 2015;2015:128084. doi: 10.1155\/2015\/128084. Epub 2015 Jan 28. No abstract available.<\/p>\r\n

PMID: 25695044<\/p>\r\n

 <\/p>\r\n

Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a phase IV, non-interventional, observational study from the European Research Initiative on Chronic Lymphocytic Leukemia.<\/a><\/p>\r\n

Moreno C, Montillo M, Panayiotidis P, Dimou M, Bloor A, Dupuis J, Schuh A, Norin S, Geisler C, Hillmen P, Doubek M, Trn\u011bn\u00fd M, Obrtlikova P, Laurenti L, Stilgenbauer S, Smolej L, Ghia P, Cymbalista F, Jaeger U, Stamatopoulos K, Stavroyianni N, Carrington P, Zouabi H, Leblond V, Gomez-Garcia JC, Rubio M, Marasca R, Musuraca G, Rigacci L, Farina L, Paolini R, Pospisilova S, Kimby E, Bradley C, Montserrat E.<\/p>\r\n

Haematologica. 2015 Apr;100(4):511-6. doi: 10.3324\/haematol.2014.118158. Epub 2015 Jan 16.<\/p>\r\n

PMID: 25596264<\/p>\r\n

 <\/p>\r\n

Has the time come to reevaluate prognostic factors and to rebuild staging systems for multiple myeloma?<\/a><\/p>\r\n

Kyrtsonis MC.<\/p>\r\n

Eur J Haematol. 2015 Feb;94(2):95. doi: 10.1111\/ejh.12429. No abstract available.<\/p>\r\n

PMID: 25689635<\/p>\r\n

 <\/p>\r\n

Immunohistochemical expression of cell cycle proteins in multiple myeloma.<\/a><\/p>\r\n

Pessach I, Papoudou-Bai A, Goussia A, Kamina S, Kyrtsonis MC, Bourantas KL, Kanavaros P.<\/p>\r\n

Leuk Lymphoma. 2015;56(9):2720-3. doi: 10.3109\/10428194.2015.1004171. Epub 2015 Feb 4. No abstract available.<\/p>\r\n

PMID: 25573203<\/p>\r\n

 <\/p>\r\n\r\n

 <\/p>","protected":false},"excerpt":{"rendered":"

HAEMATOLOGY DEPARTMENT \u2013 PUBLICATION (2015-2018)  The outcome of patients with high-risk MDS achieving stable disease after treatment with 5-azacytidine: A retrospective analysis of the Hellenic (Greek) MDS Study Group. Papageorgiou SG, Kontos CK, Kotsianidis I, Vasilatou D, Symeonidis A, Galanopoulos A, Bouchla A, Hatzimichael E, Repousis P, Zikos P, Viniou NA, Poulakidas E, Vassilakopoulos TP, […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"ngg_post_thumbnail":0,"footnotes":""},"class_list":["post-759","page","type-page","status-publish"],"_links":{"self":[{"href":"https:\/\/www.appk.gr\/en\/wp-json\/wp\/v2\/pages\/759","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.appk.gr\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.appk.gr\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.appk.gr\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.appk.gr\/en\/wp-json\/wp\/v2\/comments?post=759"}],"version-history":[{"count":12,"href":"https:\/\/www.appk.gr\/en\/wp-json\/wp\/v2\/pages\/759\/revisions"}],"predecessor-version":[{"id":1054,"href":"https:\/\/www.appk.gr\/en\/wp-json\/wp\/v2\/pages\/759\/revisions\/1054"}],"wp:attachment":[{"href":"https:\/\/www.appk.gr\/en\/wp-json\/wp\/v2\/media?parent=759"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}